Company: CERO
Filing Date: 2025-04-25
Form Type: PRE 14A
Source: 0001213900-25-035562
Chunk: 94

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-25
Form: PRE 14A
Chunk 94
---
 “Series C Certificate of Designations” ) and the Certificate of Designation of Preferences, Rights and Limitations of the Series D Convertible Preferred Stock, as amended from time to time (the “Series D Certificate of Designations” and, together with the Series A Certificate of Designations , Series B Certificate of Designations and Series C Certificate of Designations , the “Certificates of Designations”) in their entirety for a complete description of the rights and preferences of the Company’s securities. General We are authorized to issue up to 1,000,000,000 shares of Common Stock, $0.0001 par value per share (“Common Stock”), and 10,000,000 shares of preferred stock, par value $0.0001 per share (the “Preferred Stock”). As of the date of this proxy statement, the Company currently has outstanding (i) 1,429shares of Series A Preferred Stock with a conversion value of approximately $1.4million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a current effective conversion price of $1.96; (ii) 198shares of Series B Preferred Stock with a conversion value of approximately $0.2million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a floating conversion price of 80% of the lowest volume weighted average price during the five trading days immediately prior to conversion; (iii) 2,537shares of Series C Preferred Stock with a stated value of approximately $2.5million, convertible into shares of Common Stock at a conversion rate of the stated value thereof divided by a conversion price of $1.96 (iv) Series A Warrants to purchase 6,127shares of Common Stock at an exercise price of $139.00 per share; (v) Series C Warrants to purchase 81,753shares of Common Stock at an exercise price of $0.04; (vi) December 2024 and January 2025 Common Warrants to purchase an aggregate of 247,914shares of Common Stock at an exercise price ranging from $5.61 to $5.82, (vii) February 2025 Common Warrants to purchase an aggregate of 2,551,020shares of Common Stock at an exercise price of $1.96, (viii) Pre -FundedWarrants to purchase an aggregate of 215,740shares of Common Stock at an exercise price of $0.0001, and